Guest Editorial Mifepristone and the Administrative Procedure Act: Perspective of a former FDA commissioner and NCI director April 14, 2023Vol.49 No.15By Norman E. "Ned" Sharpless
Guest Editorial Leading a matrix cancer center: Extensive responsibility, modest influence, little authority April 07, 2023Vol.49 No.14By George J. Weiner
FreeGuest Editorial Ukraine’s patients had to choose: What will kill you sooner? Cancer or artillery? February 24, 2023Vol.49 No.08By Anna Uzlova and Inessa Matiushenko
FreeGuest Editorial Ukraine’s cancer care system was in the midst of an overhaul—and then Russia invaded February 24, 2023Vol.49 No.08By Viacheslav Kopetskyi
Guest Editorial The anatomy of my decision to take a PAUSE and explore life outside the cancer center director’s office February 24, 2023Vol.49 No.08By George J. Weiner
Guest Editorial ODAC clears a path for dostarlimab, a drug that may “beat the reaper” in locally advanced rectal cancer February 10, 2023Vol.49 No.06By Richard M. Goldberg
Guest Editorial A Super Bowl LVII challenge: It’s Chiefs/KU vs. Eagles/SKCC February 10, 2023Vol.49 No.06By Matthew Huesser and Christine Thomas
Guest Editorial Healing from gun violence in Asian America: What does love look like in a time of hate?天下太平 Peace under the celestial sky February 03, 2023Vol.49 No.05By Cevadne Lee
Guest Editorial NIH, NCI face devastating cuts in debt ceiling fight; We must rally for biomedical research January 27, 2023Vol.49 No.04By Lisa M. Coussens
Guest Editorial ODAC Confidential: The seven deadly sins sponsors commit again and again at FDA presentations January 20, 2023Vol.49 No.03By Mikkael A. Sekeres
